Science and Progress at the FDA: Exploring the Future of Innovation and Global Competitiveness


Science and Progress at the Food and Drug Administration (FDA):
Exploring the Future of Innovation and Global Competitiveness

Click here to register

Thursday June 16, 2011 2:00pm- 3:00pm EST
House Budget Committee Hearing Room 210
Cannon House Office Building
Washington, DC

Keynote by: Congresswoman Diana DeGette (D-CO)


Dr. Janet Woodcock, Director, CDER, FDA
Dr. Ellen Sigal, Chair, Friends of Cancer Research
Dr. John Marshall, Clinical Director of Oncology, Georgetown-Lombardi Comprehensive Cancer Center
Mr. Jonathan Leff, Managing Director, Warburg Pincus

Moderator: Kate Rawson, Senior Editor, The RPM Report

This briefing is being held in conjunction with the release of a study in Health Affairs conducted by Friends of Cancer Research that compares approval rates of cancer drugs by the U.S. Food and Drug Administration versus its European counterpart. Each year, billions of dollars are designated to biomedical research, aimed at bringing new treatments and hope to patients and families fighting illness. It is vital that we navigate what other federal agencies must do in order to allow new discoveries to improve the lives of patients. Without further development of FDA regulatory science and innovation programs, the full potential of biomedical research may be stifled.

This is a widely attended event

Friends of Cancer Research is a 501c3 Non-profit Organization